FDA lets drug makers go digital-only on prescribing info—with paper backup.
H.R. 4132 — Prescription Information Modernization Act of 2025 · Filed by Diana Harshbarger (R-TN) · 16 cosponsors · Introduced Jun 25, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill allows pharmaceutical manufacturers to provide prescribing information to doctors and pharmacists electronically instead of on paper, provided they offer the option to receive or request paper copies at no extra cost. The FDA must issue regulations within one year to implement this change and ensure healthcare professionals can still get paper versions if they want them, with a public workshop within two years to review how the digital format is working.
Why we flagged it
The bill is a straightforward amendment to FDA labeling rules, permitting digital-only prescribing information with paper-copy safeguards. It is not a carve-out or immunity grant, but a modernization of communication channels with built-in consumer/provider protections.
What the text implies
- Digital-only defaults may create accessibility barriers for prescribers in rural or under-resourced settings with unreliable internet or limited digital infrastructure, even though paper copies remain available on request.
- Manufacturers gain discretion over digital format, font, layout, and update frequency, potentially enabling subtle changes to prescribing information that are harder to track than formal label amendments.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical manufacturers (reduced paper production and distribution costs); digital health platforms and EHR vendors (potential integration opportunities); pharmaceutical packaging and logistics providers (reduced physical labeling volume)